Form 4: Bioventus Director Philip Cowdy Executes RSU Conversion

Director Philip G. Cowdy acquired 32,282 shares of Bioventus Class A common stock through the vesting of restricted stock units.

Summary

• Director Philip G. Cowdy exercised and converted 32,282 restricted stock units (RSUs) into Class A common stock on June 2, 2026.
• Following the transaction, the director holds a total of 43,982 shares of Class A common stock.
• A new grant of 25,146 RSUs was issued to the director on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation and equity alignment rather than a strategic shift or market-moving financial development.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation event.

Risks

• Future vesting of the newly granted 25,146 RSUs is contingent upon the director's continued service on the Board.

Future Outlook

The newly granted 25,146 RSUs are scheduled to vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date, provided the director remains in service.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director equity compensation, which is standard practice for publicly traded medical device companies to ensure board alignment with long-term corporate performance.

Comparison to Industry Standards

• The use of RSU-based compensation for board members is consistent with standard corporate governance practices in the healthcare and medical technology sectors.

Stakeholder Impact

• Increased alignment between the director and shareholders through higher direct equity ownership.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership